A Novel Multi-Model High Spatial Resolution Method for Analysis of DCE MRI Data: Insights from Vestibular Schwannoma Responses to Antiangiogenic Therapy in Type II Neurofibromatosis

• Main Authors: Ka-Loh Li (Author), Daniel Lewis (Author), Xiaoping Zhu (Author), David J. Coope (Author), Ibrahim Djoukhadar (Author), Andrew T. King (Author), Timothy Cootes (Author), Alan Jackson (Author)
• Format: Book
• Published: MDPI AG, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/ph16091282; 1424-8247
• Keywords: bevacizumab; DCE-MRI; neurofibromatosis type 2; prediction; treatment response; Medicine; R; Pharmacy and materia medica; RS1-441
• Source: Pharmaceuticals, Vol 16, Iss 9, p 1282 (2023)

This study aimed to develop and evaluate a new DCE-MRI processing technique that combines LEGATOS, a dual-temporal resolution DCE-MRI technique, with multi-kinetic models. This technique enables high spatial resolution interrogation of flow and permeability effects, which is currently challenging to achieve. Twelve patients with neurofibromatosis type II-related vestibular schwannoma (20 tumours) undergoing bevacizumab therapy were imaged at 1.5 T both before and at 90 days following treatment. Using the new technique, whole-brain, high spatial resolution images of the contrast transfer coefficient (K^trans), vascular fraction (v_p), extravascular extracellular fraction (v_e), capillary plasma flow (F_p), and the capillary permeability-surface area product (PS) could be obtained, and their predictive value was examined. Of the five microvascular parameters derived using the new method, baseline PS exhibited the strongest correlation with the baseline tumour volume (<i>p</i> = 0.03). Baseline v_e showed the strongest correlation with the change in tumour volume, particularly the percentage tumour volume change at 90 days after treatment (<i>p</i> < 0.001), and PS demonstrated a larger reduction at 90 days after treatment (<i>p</i> = 0.0001) when compared to K^trans or F_p alone. Both the capillary permeability-surface area product (PS) and the extravascular extracellular fraction (v_e) significantly differentiated the 'responder' and 'non-responder' tumour groups at 90 days (<i>p</i> < 0.05 and <i>p</i> < 0.001, respectively). These results highlight that this novel DCE-MRI analysis approach can be used to evaluate tumour microvascular changes during treatment and the need for future larger clinical studies investigating its role in predicting antiangiogenic therapy response.